Literature DB >> 33715328

Obstetrician-gynecologists' practice patterns regarding HPV testing in cervical cancer screening in Turkey.

Betül Akgün Aktaş1, Tayfun Toptaş2, Işın Üreyen2, Selen Doğan3, Aysel Uysal1.   

Abstract

OBJECTIVE: To determine obstetrician-gynecologists' (OBGYNs) practice patterns regarding human papillomavirus (HPV) testing in cervical cancer screening. Secondly, we aimed to examine OBGYNs' adherence to guidelines in the management of women with HPV-positive test results.
MATERIALS AND METHODS: The study was a cross-sectional survey conducted in Antalya and Istanbul provinces in Turkey using a self-reported questionnaire. A 12-item questionnaire form was administered to the participants in face-to-face interviews. Of the targeted participants, 343 OBGYNs completed the questionnaire.
RESULTS: The majority of participants, (81.0%) stated that they offered/used HPV testing in cervical cancer screening. Of those, most OBGYNs (89.9%) preferred to use HPV testing concomitant with cervical cytology (co-testing) whereas only 10.1% preferred to use HPV testing alone (primary HPV testing). The most preferred screening intervals for women with HPV-negative results were 5 years (53.4%) and 3 years (19.9%), respectively. In compliance with the guidelines, the rate of participants who recommended "referral directly to colposcopy" for women who were HPV16/18-positive and cytology-negative; and "co-testing at 12 months" for women who were positive for HPV genotypes other than HPV16/18 and cytology-negative was 53.1%. Multivariate analysis revealed that the "professional working setting" was the sole independent determinant of the adherence to the guidelines. OBGYNs working in private settings had the worst adherence rate (42.4%).
CONCLUSION: Primary HPV testing is not yet widespread among Turkish OBGYNs. Moreover, adherence to practice guidelines in the management of HPVpositive test results is relatively low. There is a need for continuing medical education regarding screening programs and the management of women with positive screening results.

Entities:  

Keywords:  Cervical cancer; HPV test; human papillomavirus

Year:  2021        PMID: 33715328      PMCID: PMC7962162          DOI: 10.4274/tjod.galenos.2021.36418

Source DB:  PubMed          Journal:  Turk J Obstet Gynecol        ISSN: 2149-9330


  15 in total

Review 1.  Cytology versus HPV testing for cervical cancer screening in the general population.

Authors:  George Koliopoulos; Victoria N Nyaga; Nancy Santesso; Andrew Bryant; Pierre Pl Martin-Hirsch; Reem A Mustafa; Holger Schünemann; Evangelos Paraskevaidis; Marc Arbyn
Journal:  Cochrane Database Syst Rev       Date:  2017-08-10

2.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.

Authors:  Debbie Saslow; Diane Solomon; Herschel W Lawson; Maureen Killackey; Shalini L Kulasingam; Joanna Cain; Francisco A R Garcia; Ann T Moriarty; Alan G Waxman; David C Wilbur; Nicolas Wentzensen; Levi S Downs; Mark Spitzer; Anna-Barbara Moscicki; Eduardo L Franco; Mark H Stoler; Mark Schiffman; Philip E Castle; Evan R Myers
Journal:  CA Cancer J Clin       Date:  2012-03-14       Impact factor: 508.702

3.  Gynecologists and human papillomavirus DNA testing: exploring knowledge, attitudes, and practice in Italy.

Authors:  Claudia Caglioti; Claudia Pileggi; Carmelo G A Nobile; Maria Pavia
Journal:  Eur J Cancer Prev       Date:  2017-05       Impact factor: 2.497

4.  An assessment of gynecological cytology screening practices among health care providers nationwide.

Authors:  May Darwish-Yassine; Ann D Garvin; Carolyn M Johnston; Lauren Zoschnick; Amy Conners; Shannon Laing; Christopher Wojcik
Journal:  Arch Pathol Lab Med       Date:  2015-05       Impact factor: 5.534

5.  Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.

Authors:  Susanne K Kjær; Kirsten Frederiksen; Christian Munk; Thomas Iftner
Journal:  J Natl Cancer Inst       Date:  2010-09-14       Impact factor: 13.506

6.  Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test.

Authors:  Thomas C Wright; Mark H Stoler; Catherine M Behrens; Abha Sharma; Guili Zhang; Teresa L Wright
Journal:  Gynecol Oncol       Date:  2015-01-08       Impact factor: 5.482

7.  Cytohistologic correlation in premenopausal and postmenopausal women.

Authors:  Syed M Gilani; Paul F Mazzara
Journal:  Acta Cytol       Date:  2013-10-01       Impact factor: 2.319

8.  Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000.

Authors:  Sophia S Wang; Mark E Sherman; Allan Hildesheim; James V Lacey; Susan Devesa
Journal:  Cancer       Date:  2004-03-01       Impact factor: 6.860

9.  Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline.

Authors:  Jose Jeronimo; Philip E Castle; Sarah Temin; Lynette Denny; Vandana Gupta; Jane J Kim; Silvana Luciani; Daniel Murokora; Twalib Ngoma; Youlin Qiao; Michael Quinn; Rengaswamy Sankaranarayanan; Peter Sasieni; Kathleen M Schmeler; Surendra S Shastri
Journal:  J Glob Oncol       Date:  2016-10-12

10.  Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women.

Authors:  Murat Gultekin; Mujdegul Zayifoglu Karaca; Irem Kucukyildiz; Selin Dundar; Guledal Boztas; Hatice Semra Turan; Ezgi Hacikamiloglu; Kamil Murtuza; Bekir Keskinkilic; Irfan Sencan
Journal:  Int J Cancer       Date:  2017-12-23       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.